石药集团(01093)：口服小分子CDK抑制剂SYH2043获临床试验批准

智通财经网2022-12-28

智通财经APP讯，石药集团(01093)公布，集团开发的SYH2043已获中华人民共和国国家药品监督管理局批准，可以在中国开展临床研究。公告称，SYH2043为具有自主知识产权的口服小分子CDK2/4/6抑制剂类创新抗肿瘤药物。临床前药效研究显示，该产品对多种实体瘤具有较好的抗肿瘤作用，尤其是对CDK4/6抑制剂塬发耐药和获得性耐药的乳腺癌。临床前药代动力学及安全性评价也显示该产品具有良好的成药性...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2294860007?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_34.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","is_english":false,"pubTime":"2022-12-28 16:43","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2294860007","market":"sh","top_or_hot":-1,"title":"石药集团(01093)：口服小分子CDK抑制剂SYH2043获临床试验批准","media":"智通财经网","content":"<div>\n<p>智通财经APP讯，石药集团(01093)公布，集团开发的SYH2043已获中华人民共和国国家药品监督管理局批准，可以在中国开展临床研究。公告称，SYH2043为具有自主知识产权的口服小分子CDK2/4/6抑制剂类创新抗肿瘤药物。临床前药效研究显示，该产品对多种实体瘤具有较好的抗肿瘤作用，尤其是对CDK4/6抑制剂塬发耐药和获得性耐药的乳腺癌。临床前药代动力学及安全性评价也显示该产品具有良好的成药性...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/853539.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>石药集团(01093)：口服小分子CDK抑制剂SYH2043获临床试验批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n石药集团(01093)：口服小分子CDK抑制剂SYH2043获临床试验批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-28 16:43 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/853539.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，石药集团(01093)公布，集团开发的SYH2043已获中华人民共和国国家药品监督管理局批准，可以在中国开展临床研究。公告称，SYH2043为具有自主知识产权的口服小分子CDK2/4/6抑制剂类创新抗肿瘤药物。临床前药效研究显示，该产品对多种实体瘤具有较好的抗肿瘤作用，尤其是对CDK4/6抑制剂塬发耐药和获得性耐药的乳腺癌。临床前药代动力学及安全性评价也显示该产品具有良好的成药性...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/853539.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/853539.html","article_id":"2294860007","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_34.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2294860007","pubTimestamp":1672217017,"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"石药集团(01093)公布，集团开发的SYH2043已获中华人民共和国国家药品监督...","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1191":"制药","BK1515":"抗疫概念","BK1141":"生命科学工具和服务","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","BK1521":"挪威政府全球养老基金持仓","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","BK1576":"医药外包概念","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","BK1583":"高瓴概念","BK4023":"应用软件","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","IE0008368742.USD":"首域中国增长基金I Acc","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","03347":"泰格医药","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","01093":"石药集团"},"translate_title":"Unacon (01093): Oral small molecule CDK inhibitor SYH2043 was approved by clinical trial","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03347":1,"CDK":1,"01093":1},"content_text":"智通财经APP讯，石药集团(01093)公布，集团开发的SYH2043已获中华人民共和国国家药品监督管理局批准，可以在中国开展临床研究。公告称，SYH2043为具有自主知识产权的口服小分子CDK2/4/6抑制剂类创新抗肿瘤药物。临床前药效研究显示，该产品对多种实体瘤具有较好的抗肿瘤作用，尤其是对CDK4/6抑制剂塬发耐药和获得性耐药的乳腺癌。临床前药代动力学及安全性评价也显示该产品具有良好的成药性及可控的安全性。集团将全力以赴推进该产品的临床研究工作，力争该产品尽快上市。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2294860007"}